Download PDF
Thromb Haemost 2012; 107(05): 803-805
DOI: 10.1160/TH12-03-0130
Invited Editorial Focus
Schattauer GmbH

Monitoring new oral anticoagulants, managing thrombosis, or both?

Hugo ten Cate
1   Department of Internal Medicine and Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands
2   Maastricht Anticoagulation Clinic, Maastricht, the Netherlands
› Author Affiliations
Further Information

Publication History

Received: 01 March 2012

Accepted after minor revision: 06 March 2012

Publication Date:
25 November 2017 (online)

    Permissions and Reprints

 

Editorial on Douxfils et al. Thromb Haemost 2012; 107: 985-997.

 

  • References

  • 1 You JJ, Singer DE, Howard PA. et al. Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e531S-575S.
    CrossrefPubMedGoogle Scholar
  • 2 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e419S-494S.
    CrossrefPubMedGoogle Scholar
  • 3 Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost 2011; 09 (Suppl. 01) 344-351.
    CrossrefPubMedGoogle Scholar
  • 4 Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011; 09 (Suppl. 01) 12-19.
    CrossrefPubMedGoogle Scholar
  • 5 Hirsh JVF. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart. Circulation 1994; 89: 1469-1480.
    CrossrefPubMedGoogle Scholar
  • 6 Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther 2008; 06: 57-70.
    CrossrefPubMedGoogle Scholar
  • 7 Wallentin L, Yusuf S, Ezekowitz MD. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
    CrossrefPubMedGoogle Scholar
  • 8 Heneghan C, Ward A, Perera R. et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379: 322-334.
    CrossrefPubMedGoogle Scholar
  • 9 Garcia-Alamino JM, Ward AM, Alonso-Coello P. et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2010; 04: CD003839.
    PubMedGoogle Scholar
  • 10 Summary annual medical report Federadion of Dutch Anticoagulation clinics. 2010 (Dutch version only) Available at: http://www.fnt.nl/pdf/Jaarvers lag_FNT_Medisch_2010.pdf
    PubMed
  • 11 Liesenfeld KH, Lehr T, Dansirikul C. et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 09: 2168-2175.
    CrossrefPubMedGoogle Scholar
  • 12 Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med 2009; 06: 101-110.
    CrossrefPubMedGoogle Scholar
  • 13 Faxon D P, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
    PubMedGoogle Scholar
  • 14 Huber K, Airaksinen KJ, Cuisset T. et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569-571.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Douxfils J, Mullier F, Robert S. et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabiagatran etixilate. Thromb Haemost 2012; 107: 985-997.
    PubMedGoogle Scholar
  • 16 van Ryn J, Stangier J, Haertter S. et al. Dabigatranet-exilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Harenberg J, Marx S, Erdle S. et al. Determination of the anticoagulant effects of new oral anticoagulants: an unmet need. Expert Rev Hematol 2012; 05: 107-113.
    CrossrefPubMedGoogle Scholar
  • 18 Schulman S, Crowther MA. How I anticoagulate in 2012, new and old anticoagulant agents, and when and how to switch. Blood. 2012 Epub ahead of print.
    PubMedGoogle Scholar
  • 19 Huisman MV, Lip G Y, Diener HC. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Pengo V, Crippa L, Falanga A. et al Italian Federation of Thrombosis Centers Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Leendertse AJ, Egberts AC, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890-1896.
    PubMedGoogle Scholar